CB-4332

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameCB-4332
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionComplement C1 modulators
TargetsComplement C1
Therapy Area/IndicationsImmunologic Deficiency SyndromesAtypical Hemolytic Uremic SyndromeGlomerulonephritis, Membranoproliferative +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCatalyst Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCatalyst Biosciences Inc
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency SyndromesAtypical Hemolytic Uremic SyndromeGlomerulonephritis, Membranoproliferative +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A